|
Published
Works
Many
of Sheldon Krimsky's published works are available for download in PDF
format from this Web site. Such works will have a PDF icon next to them.
Please note that you will need Adobe Acrobat Reader in order to download
these files. If you do not have this software, download it now:

To see
selected publications in the areas of Science & Ethics, Biotechnology,
Endocrine Disruptors, or Risk Analysis please click on the corresponding
link on the menu bar.
Full
List of Publications
176. Stop this Stealth Advertising New Scientist 202(2711):24-25 (June 5, 2009)
175. Developing Unbaised Diagnostic and Treatment Guidelines in Psychiatry-Letter New England Journal of Medicine with L. Cosgrove, H.J. Bursztajn 360 (19):2035-2036 (May 7,2009)
174. Conflicts of Interest and Disclosure in the American Psychiatric Associations's Clinical Practice Guidelines Psychotherapy and Psychosomatics with L. Cosgrove, H.J. Bursztajn, M. Anaya, & J. Walker 78:228-232:(2009)
173.
Editorial: Industry Support and its Relationship to Research Integirty Accountability in Research 16:75-77 (2009).
172.
Pharmacrops GeneWatch22:13-16 (Jan./Feb. 2009).
171. Review: Bridge at the Edge of the World In: Issues in Science & Technology Winter, 2009), pp. 89-90.
170.
When Sponsored Research Fails the Admissions Test: A Normative Framework In:Universities at Risk: How politics, special interests, and corporitization threaten academic integrity Edited by James L. Turk. Toronto, James Lorimer & Co.,Publishers, 2008
169.
Plastics in Our Diet Scientific American18(4):30-31(2008)
168. Review: Taking Action, Saving Lives In: Public Health Reports 29:256-257:(2008).
167. Chinese translation of Social Theories of Risk
166.
When Conflict-of-Interest is a Factor in Scientific Misconduct Medicine & Law26:447-463 (2007).
165.
Nauka skorumpowana?. Polish translation of Science in the Private Interest
164.
Risk Communication in the Internet Age: The Rise of Disorganized Skepticism Environmental Hazards 7:157-164 (2007).
163.
A New Era of DNA Collections: At What Cost to Civil Liberties? with T. Simoncelli American Constitution Society for Law and Policy(September 2007).
162.
Testing Pesticides in Humans: Of Mice and Men Divided by Ten with T. Simoncelli JAMA 297(21):2405-2407 (June 6, 2007).
161.
The Birth of Synthetic Biology and the Genetic Mode of Production Genetically Engineered Crops: Interim Policies, Uncertain Legislation Edited by Iain E.P. Taylor. Haworth Press, 2007
160.
Publication Bias, Data Ownership, and the Funding Effect in Science: Threats to the Integrity of Biomedical Research Rescuing Science from Politics: Regulation and the Distortion of Scientific Research Edited by W. Wagner and R. Steinzor. Cambridge University Press, 2006
159.
Review: Origins of the Organic Agriculture DebateIn: ISIS 97(2):378-379 (2006).
158.
The Ethical and Legal Foundations of Scientific 'Conflict of Interest' Law and Ethics in Biomedical Research: Regulation, Conflict of Interest, and Liability Edited by Trudo Lemmens and Duff R. Waring. University of Toronto Press, 2006
157.
Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry. with L. Cosgrove, M. Vijayaraghawan, & L. Schneider Psychotherapy and Psychosomatics 75:154-160 (2006).
156.
Fraudulent Human Embryonic Stem Cell Research in South Korea: Lessons Learned. With D, B. Resnik and A. E. Shamoo. Accountability in Research 13:101-109 (2006).
155.
Autonomy, Disinterest, and Entrepreneurial Science Society 43(4):22-29(May/June 2006).
154.
Review: University Inc.Jennifer Washburn Academe 91(5):63-64(September/October 2005).
153.
Review: Recoding Nature: Critical Perspectives on Genetic EngineeringR. Hindmarsh and G. Lawrence, eds. The Quarterly Review of Biology 80:474(2005).
152.
From Asilomar to Industrial Biotechnology: Risks, Reductionism and Regulation Science as Culture 14(4):309-323(December 2005).
151.
China's Gene Therapy Drug GeneWatch Vol 18, No. 6 (December 2005).
150.
The Weight of Scientific Evidence in Policy and Law American Journal of Public Health (Supplement) 95(S1):S129-S136(2005).
149.
Review: The Great BetrayalHorace Freeland Judson. Harcourt, Inc. 2004. Nature Medicine 11(6):591 (June 2005).
148.
The Funding Effect in Science and its Implications for the Judiciary Journal of Law and Policy Vol. XIII, No.1 (2005).
147.
Rights and Liberties in the Biotech Age. Roman and Littlefield Pub. Edited with Peter Shorett. Rowman & Littlefield Pubs. 2005.
146.
Emergence of a Scientific and Commercial R&D Infrastructure for Human Gene Therapy. (with Christine Crofts) Human Gene Therapy16:169-177(February 2005).
145.
Introduction to Special Issue of Accountability in Research on Conflict of Interest. In:Accountability in Research11:79-81(April-June 2004).
144.
La Recherche Face Aux Interet Prives. French version of Science in the Private Interest. Trans. by Lena Rozenberg. Preface: La Mouche et Le Tigre, by d'Isabelle Stengers.Paris, Le Seuil, 2004.
143.
Reforming Research Ethics in an Age of Multivested Science. In:Buying in or Selling Out? Donald G. Stein,ed. New Brunswick, NJ: Rutgers University Press, 2004.
142.
Review: Is Fluoride Really Safe? Christopher Bryson Chemical and Engineering News 82:35-36 (August 16, 2004).
141.
Small Gifts, Conflicts of Interest, and the Zero-Tolerance Threshold in Medicine. American Journal of Bioethics.3:50-52(Summer 2003).
140.
Review: The Hope, Hype and Reality of Genetic EngineeringJohn C. Avise. Oxford University Press, 2004. The Quarterly Review of Biology 79:506-507 (September 2004).
139.
Science on Trial GeneWatch 16(5):3-6 (September-October 2003).
138.
Review: The Greatest Experiment ever Performed on Women Public Health Reports 24(3/4):479-483 (2003).
137.
Implicit precaution, scientific inference, and indirect evidence: the basis for the U.S. Environmental Protection Agency's regulation of genetically modified crops. New Genetics and Society. 22:127-143(August 2003).
136.
Science in the Private Interest Lanham: MD: Rowman & Littlefield, 2003..
135.
Biotechnology at the dinner table: FDA oversight of transgenic food. Annals of the American Academy of Political and Social Science. 584:80-96 (November 2002).
134.
Environmental impacts of the releases of
genetically modified organisms. Encyclopedia of Pest Management.
David Pimental, ed. N.Y.: Marcel Dekker, Inc., 2002.
133. Ethical issues involving the production, planting, and distribution of genetically
modified crops. Engineering the Farm.
Edited by Marc Lappe and Britt Bailey. Boulder, CO: Island Press, 2002.
132.
An Epistemological Inquiry into the Endocrine
Disruptor Hypothesis. Annals of the New York Academy of Sciences
948:130-142(2002).
131.
Commentary on the retraction of scientific
articles. Nature Genetics 30:139(February 2002).
130.
Endocrine disruptors--A controversy
in science and policy: Summary and research needs. Neurotoxicology
22:557-558 (October 2001).
129.
Patentability of biotechnology inventions
under the PTO utility guidelines: Still uncertain after all these years.
Journal of Biolaw & BioBusiness. Special Supplement: Intellectual
Rights and Patent Rights 2001 (with Warren A. Kaplan).
128. Japanese
edition of Hormonal Chaos 2001. Tokyo: Fujiwara Publishing
Co.
127.
Journal Policies on Conflict of Interest:
If this is the Therapy, What's the Disease [Editorial]. Psychotherapy
and Psychosomatics 70:115-117(2001).
126.
Hormone Disruptors: A Clue to Understanding
the Environmental Causes of Disease. Environment 43:22-31(June
2001).
125.
The RDNA Wars. Review of The Recombinant
DNA Controversy: A Memoir by Donald S. Fredrickson. American
Scientist 89:564-565(November-December 2001).
124.
Conflict of Interest Policies in Science and
Medical Journals: Editorial Practices and Author Disclosures. (with
L.S. Rothenberg). Science and Engineering Ethics 7:205-218(April
2001).
123.
Transdisciplinarity for Problems at the Interstices
of Disciplines. In Transdisciplinarity: Recreating Integrative
Knowledge, M.A. Somerville and D.J. Rapport, eds. Oxford, UK:
EOLSS Publishers Co. Ltd., 2000, pp.109-114.
122. Scientific
journals and their authors' financial interests (reprinted). In: The
Commercialization of Genetics Research. T.A. Caulfield and B.
William-Jones, ed. New York: Kluwer Academic Publishers, 2000.
121. Commentary
on "Politics of Certainty." Science and Engineering Ethics
6(4):509-510 (2000).
120.
Environmental Endocrine Hypothesis and Public Policy.In: Illness and the Environment.Steve Kroll-Smith, Phil Brown, and Valerie J. Gunter, eds. New York University Press, 2000
119.
Risk Assessment and Regulation of Bioengineered
Food Products. International Journal of Biotechnology.
2(1/2/3):231-238 (2000).
118.
The Psychosocial Limits of Human Germline Modification.In: Engineering the Human Germline. G.Stock and J. Campbell, eds. Oxford, 2000.
117.
Conflicts of Interest and Cost-effectiveness Analysis
[Editorial] JAMA 282:1474-6 (October 20, 1999).
116. Hormonal
Chaos: The Scientific and Social Origins of the Environmental Endocrine
Hypothesis. Johns Hopkins University Press, 2000.
115.
The Profit of Scientific Discovery and its
Normative Implications. Chicago Kent Law Review. 75(1):15-39(1999).
114.
Eureka! New Ideas in Cell Biology. Review
of Society of Cells by C. Sonnenschein & A. Soto. BioScience.
49(9):747-8(September 1999).
113.
The Precautionary Approach. Forum
for Applied Research & Public Policy 13(3):35-38(Fall 1998).
112.
Transgenic Agriculture: Biotechnology and
International Trade. Journal of Science and Technology Law
4(Spring 1998).
111.
Review: Research Misconduct: Issues, Implications
and Strategies, E. Altman and P. Hernon, eds. NEJM
339(8):568(August 20, 1998).
110.
Financial Interest and its Disclosure in Scientific
Publicatons. (w. L.S. Rothenberg). JAMA 280(3):225-226(July
15, 1998).
109.
Review: The Biotech Century: Harnessing
the Gene and Remaking the World. Nature 393:31-32(May
7, 1998).
108. The
Cultural and Symbolic Dimensions of Agricultural Biotechnology, adapted
for Private Science: Biotechnology and the Rise of the Molecular
Sciences, Arnold Thackray, ed. University of Pennsylvania Press,
1998.
107.
Scientific Journals and Their Authors' Financial
Interests: A Pilot Study (w. L.S Rothenberg, P. Stott, and G. Kyle).
Psychotherapy and Psychosomatics 67(4-5):194-201(1998).
Reprinted in: The Commercialization of Genetic Research
T.A. Caulfield and B. Williams-Jones, eds. New York: Kluwer, 1999.
106.
Review. Technical Trajectories and
the Human Environment. J.H. Ausubel and H.D. Langford, eds. National
Academy Press, Washington D.C., 1997; Linking Science and Technology
to Society's Environmental Goals. Policy Division, National Research
Council, National Academy Press. Washington D.C., 1996. Nature Biotechnology
15:1014-1015(October 1997).
105.
Review. Enabling the Safe Use of Biotechnology:
Principles and Practice and Appropriate Oversight for Plants with Inherited
Traits for Resistance to Pests. Environment 39(5):27-30(June
1997).
104.
Revolution of Evolution? [In Biotechnology]
Future. Special Edition on Biotechnology, II May 1997, pp. 14-17.
103.
Review. Dealing with Risk by Howard Margolis.
The Annals of the American Academy of Political and Social Science.
554:230-231(Nov.1997).
102.
Regulatory Oversight of Genetically Engineered
Microorganisms: Has Regulation Inhibited Innovation? (with R. Wrubel
and M. Anderson). Environmental Management 21(4)571-586(1997).
101.
Financial Interest of Authors in Scientific
Journals: A Pilot Study of 14 Publications (with Rothenberg, Stott
and Kyle). Science and Engineering Ethics 2(4):395-410(1996).
100. Three
Food Safety Issues: Life Cycle of Technical Controversies and the Social
Selection of Risks. Working Paper #3. Center for Agriculture, Food
and Environment; Tufts University School of Nutrition. October
1995.
99. Commentary:
"The Hazards of Whistleblowers and on Some Problems of Young Biomedical
Scientists in our Time" by John Edsall. Science and Engineering
Ethics 1(4):341-344(1995).
98.
Risk Assessment of Genetically Engineered Microorganisms: From Genetic Reductionism to Ecological Modeling. Prepared for the International Society for the History and Philosophy of the Biological Sciences, Leuven, Belgium, July 20, 1995.In: Coping with Deliberate Release: The Limits of Risk
Assessment Ad van Dommelon, ed. Tilberg/Buenos Aires: International
Center for Human & Public Affairs, 1996.
97. Review
of Gene Wars: Science, Politics and the Human Genome by Robert
Cooke-Deegan. In Politics and the Life Sciences 15(1):130-1(Feb.
1996).
96.
A Role for Standardized Microcosms in the
Risk Assessment of Genetically Engineered Microorganisms. BioScience 45(9):590-599 (October, 1995). (with R.P. Wrubel, S.B. Levy, R.E. Wetzler, & B. Marshall).
95. Editorial.
The Future of the Recombinant DNA Advisory Committee. Human Gene
Therapy 5:1313-4(November 1994).
94. Science,
Money and Innovation. [Review]. Profits of Science by Robert Teitelman.
Forum for Applied Research and Public Policy. 10(4):146-7(Winter1995).
93.
The Environmental Endocrine Hypothesis and Public Policy. Comments on Toxicology5(4-5):487-502. 1996.
92. The
Cultural and Symbolic Dimensions of Agricultural Biotechnology. In Issues
in Agricultural Bioethics, T.B. Mepham, G.A. Tucker, J. Wiseman,
eds. Nottingham: Nottingham University Press, 1995, pp. 1-18.
91. The Business of Research. (w. Ruth Hubbard) Hastings Center Report25(1):41-43 (Jan/Feb 1995).
90.
Science, Society, and the Expanding
Boundaries of Moral Discourse. Science, Politics and Social
Practice. Boston Studies in the Philosophy of Science.
Dordrecht:Kluwer, 1995.
89. Agricultural
Biotechnology & the Environment. (with Roger Wrubel).
Champagne, IL: University of Illinois Press. 1996.
88. Review:
Democratic Values and Technological Choices. Stuart Hill. Stanford
Univ. Press, 1992. In American Scientist 82:90-91(January-February
1994).
87. Review:
The Social Costs of Genetic Welfare by Marque-Luisa Miringoff.
Rutgers Univ. Press 1991. In Social Science Quarterly 74(1):230-232
(March 1993).
86. Review:
Gene Mapping: Using Law and Ethics as Guides, George G. Annas and
Sherman Elias, eds. 1992. In Social Science & Medicine
38(1):199-200.
85. Risk
Analysis and Public Policy. Environment. 35(2):5;40-41(March
1993).
84.
Field Testing Transgenic Plants: An Analysis
of USDA's Environmental Assessments. (with R. Wrubel and R. Wetzler).
BioScience 42(4):280-289 (April 1992).
83.
Evaluating Risk Communication: Narrative versus Technical Presentations of Information about Radon (with D. Golding and A. Plough).
Risk Analysis 12(1):27-35 (1992).
82. Social
Theories of Risk. (with D. Golding, ed.) Westport, CT: Praeger,
1992.
81.
Factoring Risk Into Environmental Decision Making (with D. Golding) In: Environmental Decision Making: A Multidisciplinary Perspective. R. Chechile
and S. Carlisle, eds. NY: Van Nostrand Reinhold, 1991.
80. Techno
farming [Review]. Plants, Power and Profit by L. Busch et al. Nature
350:568 (April 18, 1991).
79. Academic Corporate Ties in Biotechnology: A Quantitative Study. Science,Technology &Human Values16(3):275-287 (Summer 1991).
78. Biotechnics and Society: The Rise of Industrial Genetics. NY: Praeger,
1991.
77. Human Gene Therapy: Must We Know Where to Stop before We Start Human Gene Therapy1(2):171-173(Summer 1990).
76. Translation
of Ch. 3 "Release of Gentically Engineered Organisms into the Environment"
from Environmental Hazards into Danish. Udsactning Af Genspejsede
Organismer. 1 Miljoet "Is Minus-Sagen." Jesper Toft, ed. Copenhagen:
Noah, 1988. Gen Debat 3.
75. Biotechnology's
Benefits Can Only Be Assured Through Controls. Opposing Viewpoints.
Sources. Science & Technology. Vol. 1. St. Paul, MN: Greenhaven
Press, 1987.
74. Assessing
the Progress of the Genetics Revolution. 1988 Telegen Annual.
NY: Bowker Pub. Co., 1989.
73. Fetal
Research in the United States: A Historical and Normative Perspective.
In Artificial Procreation: The State of Ethics and Law.
C. Byk, ed. Paris: Masson, 1989.
72.
Controlling Risk in Biotech. (with K.
Bergmann, N. Conell, S. Schulman, & N. Wilker). Technology Review
92(5):62-70 (July 1989).
71. Biopolitics:Looking
for a Home [Commentary]. Issues in Science & Technology
4(4):29(Summer 1988).
70. Risky
Science: Is Anybody Watching the Experimental AIDS Mouse? The Scientist
May 16, 1988, pp. 11-12.
69. Carrying
the Baconian Torch [Review]. Controlling Life: Jacques Loeb and the
Engineering Ideal in Biology. In Hastings Center Report,
June.July 1988.
68. Jeux
Sans Frontieres [Review]. The Biotechnology Revolution: An International
Perspective by A.M. Russell. NY: St. Martin's Press, 1988. InNature334:111-112(July
14, 1988).
67. Science, Biopolitics and Risk: Margins of Uncertainty Politics and the Life Sciences7:140-142 (February 1989).
66.
University Entrepreneurship and the Public Purpose. Biotechnology: Professional Issues and Social Concerns. P. DeForest, M.S. Frankel, J.S. Poindexter, and V. Weil,eds. Washington DC: American Association for the Advancement of Science. October 1988.
65. Environmental Release of Genetically Engineered Organisms: Recasting the Debate (w. K. Bergman, N. Connell, S. Shulman, N. Wilker).GeneWatch 5(2-3):1-3;6-7(1988).
64. Environmental Hazards: Communicating Risks as a Social Process.
Auburn House Pub. Co., 1988 (w. A. Plough).
63. Review:Biotechnology: The University-Industry Complex by Martin Kenney. New Haven: Yale University Press, 1987. In American ScientistSept-Oct. 1987, p. 549.
62.The Emergence of Risk Communication Studies: Social and Political Context (w. A. Plough). Science, Technology & Human Values 12(3&4):4-10(Summer-Fall 1987).
61. Science
and Politics in Transition: Making Sense of Biotechnology Policy [Review]:
Biotechnology in Society, J.G.Perpich (ed.); and Biotechnology:
Implications for Public Policy, S. Panem (ed.). In Politics
and the Life Sciences 6(1):122-124 (Aug.1987).
60. Review:
Read the Label: Reducing the Risk by Providing Information by Susan
Hadden. In Science, Technology and Human Values 12(2):65-66(Spring
1987).
59.
The New Corporate Identity of the American University. Alternatives 14(2):20-29 (May/June 1987).
58. Beyond
the Technical Problems of Intentional Release (with D. Andow, J. Doyle,
and C. Nader). In Prospects for Physical and Biological Containment
of Genetically Engineered Organisms, James W. Gillett (ed.). Ecosystems
Research Center Report no. 114, March 1987.
57. The
Socio-Historical Context of the Debate Over Deliberate Release. In Application
of Biotechnology: Environmental and Policy Issues. John R. Fowle
III (ed.). Washington, D.C.: Westview Press, 1987.
56. The
Regulatory Quandary Over Biotechnology. Proceedings of the Washington
International Conference on Biotechnology. April 21-22, 1986.
55.
Research Under Community Standards: Three Case Studies. Science, Technology & Human Values.11(3):14-33 (Summer 1986).
54. Biologists
Under Control [Review]. The Politics of Regulating Recombinant DNA
Research in Britain by David Bennett, Peter Glasner and David Travis
and Cloning and the Constitution: An Inquiry into Governmental Policymaking
and Genetic Experimentation by Ira H. Carmen.Nature
21:735-736(June 19, 1986).
53. Legislacion:
Desarrollo en EE.UU. (1973-1982). La Ingenieria Genetica y Sus Aplicaciones.
Jose R. Pellon (ed.). Traducido al castellano por Miguel Zamora. Zaragoza,
Spain, Acribia, S.A., 1986, pp.199-215.
52.
Local Control of Research Involving Chemical Warfare Agents. In: Governing Science and Technology in a Democracy. Malcolm L. Goggin (ed.). Knoxville, TN: University of Tennessee Press, 1986, 194-217.
51. The
New Corporate Identity of the American University. Proceedings of
an International Symposium: Universities in the Twenty-first Century.
October 23-25, 1985, University of New Hampshire, Durham, New Hampshire.
50. Social
Responsibility in an Age of Synthetic Biology: Beyond Biohazards. InThe
Gene-splicing Wars: Reflections on the Recombinant DNA Controversy.
R. Zilinskas and B.K. Zimmerman, (eds.). N.Y.:Macmillan Pub. Co., 1986.
49. United
States and Canadian Governmental Regulations Concerning Biohazardous Effluents.
(with A.H. Fraenkel). In Comprehensive Biotechnology. Murray
Moo-Young ed.in chief. Vol.4. The Practice of Biotechnology,
1986, pp.609-631.
48. Private
Sector Science and the Community: The Morris Township-Bellcore Case. The
Regulatory Environment for Science: Social Restraints and Legal Controls
of Research. Marcel LaFollette (ed.). Washington, D.C.: Office
of Technology Assessment, February 1986.
47. Comparison
of Two Cases of Community Control of Research. The Regulatory Environment
for Science: Social Restraints and Legal Controls of Research.
Marcel LaFollette (ed.). Washington, D.C.: Office of Technology Assessment,
February 1986.
46. The
Corporate Capture of Genetic Technologies. Science for the People.
Special Issue: De-coding Biotechnology. 17(3):32-37 (May/June 1985).
45. Review:
The Gene Business by Edward Yoxen. The Quarterly Review of
Biology 60:74-75 (March 1985).
44. The
Corporate Capture of Academic Science and its Social Costs. Genetics
and the Law III. Proceedings of the Third National Symposium on
Genetics and the Law, April 2-4, 1984. Aubrey Milunsky and George Annas
(eds.). New York: Plenum Press, 1985, pp. 45-55.
43. Regulation
of Biotechnologies: State and Local Roles and Initiatives. Biotechnology
and the Environment: Risk & Regulation. A.H. Teich, M.A. Levin,
and J.H. Pace (eds.). Washington, D.C.: American Association for the Advancement
of Science, 1985, pp. 159-177.
42.
Epistemic considerations on the value of folk-wisdom in science and technology..Policy Studies Review 3(2):245-262(February 1984).
41. Beyond
Technocracy: New Routes for Citizen Involvement in Social Risk Assessment.
Citizen Particpation in Science Policy. James C. Peterson,
ed. Amherst, MA: Univ. Mass. Press, 1984, pp. 43-62. Reprint of J.
Voluntary Action Research.
40. Pure
Science and Impure Scientists: Dilemmas for Public Policy. Politics
and the Life Sciences. 3(1):49-51 (Aug 1984).
39. Genetic
Alchemy. Japanese translation. 1984. Japanese editor, Rihito Kimura.
Ie-No-Hikari Assoc. Tokyo, Japan.
38. Regulatory
Policies on Biotechnology in Canada. A contracted report for the
Science Council of Canada, February 1984. Published by the Council, Fall
1984.
37. Development
of Biotechnology Policy and Regulations in the U.S.: 1982-1983. Telegen
Annual Review. Genetic engineering abstracts. New York: Environmental
Information Center, 1984.
36. Social
Risk Assessment and Group Process. Group Decision Making: Interdisciplinary
Perspectives. W.C. Swap, ed. Sage Pub.,1984.
35. Municipal
and State Recombinant DNA Laws: History and Assessment. (with
A. Baeck and J. Bolduc). Medford, MA: Dept. Urban and Environmental Policy,
Tufts University, June 1982.
34. Review.
Progress and Its Discontents G.A. Almond, M. Chodorow, and R.H.
Pearce, eds. Environmental Professional 5(3&4),(1983).
33. Review.
Alternatives to Regulation by M.S. Baram. Environmental Affairs
Law Review 10(2):579-582 (1982).
32. Science
Perverted: Can It Happen Here? [Review]. Politics and the Restraint
of Science by L.A. Cole.Hastings Center Report 13(6):42-43
(December 1983).
31.
Biotechnology and Unnatural Selection: The Social Control of Genes..Technology and Social Change A Festschrift for Eugene A. Wilkening. Gene
F. Summers (ed.) Boulder, CO: Westview Press, 1983, pp. 51-70.
30. Development
of Recombinant DNA Policy and Regulations in the U.S.: 1981-1982. Telegen
Annual Review, Index and Yearbook, 1982. Genetic Engineering Abstracts.
New York: Environmental Information Center, January1983.
29.
Social Responsibility in an Age of Synthetic Biology. Environment.24(6):2-5;8-11 (July-August 1982).
28. Development
of Recombinant DNA Policy and Regulations in the U.S., 1973-1980. Biotechnology
Emerges:1973-1980 the Key Years. Telegen Annual Review.
Genetic Engineering Abstracts. NY:Environmental Information Center, November
1982.
27. Local
Monitoring of Biotechnology: The Second Wave of RDNA Laws. Recombinant
DNA Bulletin 5(2):79-85 (June 1982).
26. Beyond
Technocracy: New Routes for Citizen Involvement in Social Risk Assessment.
Journal of Voluntary Action Research 11(1):8-2 (Jan.-Mar.
1982).
25. Regulating
Genetic Engineering. Published debate with Bernard Fields. The Harvard
Health Letter. August, 1981.
24. The
Political Economy of Environmental Issues. The Radical Teacher
7(19):6-8 (1981).
23. Genetic
Alchemy: The Social History of the Recombinant DNA Controversy.
Cambridge, MA: The MIT Press, 1982.
22. Patents
for Life Forms Sui Generis: Some New Questions for Science, Law, and Society.
Recombinant DNA Technical Bulletin 4(1):11-15 (April 1981).
21. Genetic
Technology: The Future of Regulation. Proceedings of the Battelle
International Conference on Genetic Engineering, April 6-10, 1981,
Reston, VA.
20.
Patenting of Microorganisms and Higher Life Forms: Social and Ethical Concerns..Patenting of Microorganisms: Issues and Questions. Robert F. Acker and Moselio Schaechter (eds.) Washington D.C.: American Society for Microbiology, 1981, pp. 17-22.
19. Value
Issues in the Controversy over Recombinant DNA Research. A Study funded
by the Program in Ethics Values in Science and Technology (EVIST), National
Science Foundation. Five parts, approx. 1000 pp. The Social and Political
Context, Part 1, Vol. I.; The Asilomar Period, Part 2, Vol. II; The Origins
of Public Involvement, Part 3, Vol. II; Scientific and Policy Debates,
Part 4, Vol. III. Papers and Essays, Part 5, Vol. IV. 1981.
18.
The Ties That Bind. Published Debate with David Baltimore. Nature.283:130-131(January 10, 1980).
17. A Comparative
view of state and municipal laws regulating the use of recombinant DNA
molecule technology. Recombinant DNA Technical Bulletin
2(3):121-125(November 1979).
16.
Book Review: Core of controversy over biohazards. The Recomnbinant DNA Debate In: Nature 282:170-171 (November 8, 1979).
15.
Recombinant DNA Research: The Scope and Limits of Regulation. with David Ozonoff. American Journal of Public Health 69:1252-125 (December 1979.
14. Public
Participation in the Formation of Science and Technology Policy. Report
prepared under contract from the Directorate for Scientific, Technological
and International Affairs (STIA), National Science Foundation, March 1979.
13. Citizen
Participation in Scientific and Technological Decisionmaking. Citizen
Participation Perspectives. Stuart Langton, ed. Proceedings of
the National Conference on Citizen Participation, Lincoln Filene Center,
Tufts University, 1979.
12.
A Citizen Court in the Recombinant DNA Debate Bulletin of the Atomic Scientists34:37-43 (October 1978)
11. An Experiment
in Environmental Education for Citizen Advocates. (with J. DeNeufville).
Journal of Alternative Higher Education. 2(3):210-222 (Spring
l978).
10. Regulating
Recombinant DNA Research. Controversy: Politics of Technical Decisions.
Dorothy Nelkin (ed.). Beverly Hills, CA: Sage Pub., 1978.
9. Paradigms
and Politics: The Roots of Conflict Over Recombinant DNA Research. Science
and the Public Interest: Recombinant DNA Research. R.P. Bareikis,
ed. 1978. Proceedings of a forum held at Indiana University, November
10-12, 1977.
8.
The Recombinant DNA Controversy and the Public Interest Chemical & Engineering News 55:36-41 (May 30, 1977).
7.
The Cambridge Experimentation Review Board Bulletin of the Atomic Scientists 33(5):23-27 (May 1977).
6.
On Deductive Non-Nomological Explanation Philosophia Bar-Ilan University, Israel. 6(2):303-308 (June 1976).
5.
On Thought Experiments Philosophical Forum (with W.D. Price) A translation and adaptation of a work by Ernst Mach (1897) "Uber Gedankenexperimente."
4(3): 446-457 (Spring 1973).
4. The Scientist
as Alienated Man. Science, Technology and Freedom. W.H.
Truitt and T.W.G. Solomons, eds. pp.169-176.
3.
The Use and Misuse of Critical Gedankenexperimente Zeitschrift fur Algemeine Wissenschaftstheorie 4(2):323-334 (1972), Dusseldorf, Germany.
2. The Multiple World Experiment and Absolute Space. Nous 6(3):266-273 (September l972).
1.
The Gamma Function and Stirling's Approximation The Brooklyn College Journal of Science 1963.
Back
to top
Home | Bio |
Publications | Science
& Ethics Publications | Biotechnology
Publications | Endocrine Disruptors Publications
| Risk Analysis Publications |
Books | Commentaries
|
Book Reviews
| Courses |
Links
|